ГоловнаArchive of numbers2022Volume 30, issue 1 (110)Protocol for the treatment of patients with multiple sclerosis using bone marrow stromal cells (BMSC) in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine"
Title of the article Protocol for the treatment of patients with multiple sclerosis using bone marrow stromal cells (BMSC) in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine"
Authors Voloshyna Natalia
Vasylovskyi Vitalii
Chernenko Maksym
In the section HELP TO PRACTICAL PHYSICIAN
Year 2022 Issue Volume 30, issue 1 (110) Pages 85-90
Type of article Scientific article Index UDK Index BBK -
Abstract DOI: https://doi.org/10.36927/2079-0325-V30-is1-2022-16
Key words
Access to full text version of the article pdf download
Bibliography 1. Muratova T. M., Nehrych T. I., Voloshyna N. P. ta in. Rozsiianyi skleroz v Ukraini: personalizovana stratehiia likuvannia. Zdorovia Ukrainy. 2020. No. 2. S. 14—16. URL: https://health-ua. com/multimedia/5/0/2/7/4/1593093235.pdf.
2. E. G. Celius, H. Thompson, M. Pontaga [et. al.] Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives. Patient Prefer Adherence. 2021. Vol. 15. P. 15—27. DOI: 10.2147/PPA.S268829.
3. X. Montalban, R. Gold, A. J. Thompson et al. ECTRIMS/ EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 2018. No. 24(2). Р. 96—120. DOI: 10.1177/1352458517751049.
4. H. P. Hartung, R. Gonsette, N. Konig et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet. 2002. No. 360 (9350). Р. 2018—2025. DOI: 10.1016/S0140-6736(02)12023-X.
5. X. Montalban, S. L. Hauser, L. Kappos et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017. No. 376 (3). Р. 209—210. DOI: 10.1056/ NEJMoa1606468.
6. M. F. Pittenger, A. M. Mackay, S. C. Beck et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999. Vol. 284. Р. 143—147. DOI: 10.1126/science.284.5411.143.
7. N. R. Blondheim, Y. S. Levy, T. Ben-Zur et al. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev. 2006. Vol. 15, no. 2. Р. 141—164. DOI: 10.1089/scd.2006.15.141.
 8. Kassis I., Vaknin-Dembinsky A., Karussis D. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection. Curr Stem Cell Res Ther. 2011. Vol. 6, Issue 1. Р. 63—68. DOI: 10.2174/157488811794480762.
9. Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007. Vol. 28, Issue 5. Р. 219—226. DOI: 10.1016/j.it.2007.03.001.
10. Ben-Hur T. Immunomodulation by neural stem cells. J Neurol Sci. 2008. No. 265 (1-2). Р. 102—104. DOI: 10.1016/j. jns.2007.05.007.
11. Nauta A. J., Fibbe W. E. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007. No. 110 (10). Р. 3499—3506. DOI: 10.1182/blood-2007-02-069716.
12. I. Kassis, N. Grigoriadis, B. Gowda-Kurkalli et al. Neuroprotection and immunomodulation with mesenchymal stem  cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol. 2008. No. 65 (6). Р. 753—761. DOI: 10.1001/ archneur.65.6.753.
13. E. Zappia, S. Casazza, E. Pedemonte et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005. Vol. 106, Issue 5. Р. 1755—1761. DOI: 10.1182/blood-2005-04-1496.
14. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008. No. 8 (9). Р. 726—736. DOI: 10.1038/nri2395.
15. V. K. Harris, Q. J. Yan, T. Vyshkina et al. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci. 2012. No. 313 (1-2). Р. 167—177. DOI: 10.1016/j.jns.2011.08.036.
16. Antonio Uccelli, Alice Laroni, Mark S Freedman, Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011. No. 10 (7). Р. 649—656. DOI: 10.1016/S1474-4422(11)70121-1.
17. S. Pluchino, A. Quattrini, E. Brambilla et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. 2003. 422: 688—94. DOI: 10.1038/ nature01552.
18. S. Pluchino, E. Blezer, S. Amadio et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in nonhuman primates. Ann Neurol. 2009. No. 66 (3). P. 343—354. DOI: 10.1002/ana.21745.
19. T. Ben-Hur, O. Einstein, R. Mizrachi-Kol et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia. 2003. Vol. 41, Issue 1. Р. 73—80. DOI: 10.1002/ glia.10159.
20. Dimitrios Karussis, Panayiota Petrou, Ibrahim Kassis, Clinical experience with stem cells and other cell therapies in neurological diseases. J Neurol Sci. 2013. Vol. 324. Р. 1—9. DOI: 10.1016/j.jns.2012.09.031.
21. J. Chen, Y. Li, L. Wang, M. Lu et al. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci. 2001. Vol. 189. Р. 49—57. DOI: 10.1016/S0022-510X(01)00557-3.
22. D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010. 67 (10). Р. 1187—1194. DOI: 10.1001/archneurol.2010.248.
23. P. H. Lee, J. E. Lee, H. S. Kim et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012. 72 (1). Р. 32—40. DOI: 10.1002/ana.23612.
24. P. Petrou, Y. Gothelf, Z. Argov et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016. 73 (3). Р. 337—344. DOI: 10.1001/jamaneurol.2015.4321. 25. J. D. Berry, M. E. Cudkowicz, A. J. Windebank et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, biomarker results. Neurology. 2019. 93 (24). Р. 2294—2305. DOI: 10.1212/WNL.0000000000008620.
26. D. Karussis, I. Kassis, B. G. Kurkalli, S. Slavin, Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci. 2008. Vol. 265, Issues 1—2. 265. Р. 131—135. DOI: 10.1016/j.jns.2007.05.005.
27. J. D. Glass, V. S. Hertzberg, N. M. Boulis et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016. 87 (4). Р. 392—400. DOI: 10.1212/WNL.0000000000002889.
28. Voloshina N. P., Vasilovskiy V. V., Mikulinskiy Yu. E., Schegelskaya E. A. Autoterapiya kletkami stromyi kostnogo mozga (KSKM), indutsirovannyimi v nervnyie, bolnyih s hronicheskimi zabolevaniyami TsNS (rasseyannyiy skleroz, bolezn Parkinsona). Ukrainskyi neirokhirurhichnyi zhurnal. 2003. No. 3. URL: https://cyberleninka.ru/article/n/autoterapiyakletkami-stromy-kostnogo-mozga-indutsirovannymi-v-nerv....
29. V. K. Harris, J. Stark, T. Vyshkina et al. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine. 2018. No. 29. Р. 23—30. DOI: 10.1016/j.ebiom.2018.02.002.
30. E. Eggenhofer, V. Benseler, A. Kroemer et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012. No. 3. Р. 297. DOI: 10.3389/fimmu.2012.00297.
31. Voloshyna N. P., Vasylovskyi V. V., Mikulynskyi Yu. Yu., Shchehelska O. A. «Sposib likuvannia khvorykh na rozsiianyi skleroz» vid 02.10.2003. Kyiv. Ukrpatent. patent UA 68711 A.
32. Voloshina N. P., Vasilovskiy V. V. Eticheskie voprosyi v lechenii bolnyih rasseyannyim sklerozom (autoterapiya stromalnyimi kletkami kostnogo mozga, indutsirovannyimi v nervnyie). Kultura narodov Prichernomorya. 2004. No. 56. T. 2. S. 185—186.
33. Karussis D., Kassis I. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. Clin Neurol Neurosurg. 2008. No. 110 (9). Р. 889—896. DOI: 10.1016/j.clineuro.2008.02.008.
34. P. M. Connick, C. Crawley, D. J. Webber et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proofof-concept study. Lancet Neurol. 2012. No. 11 (2). Р. 150—156. DOI: 10.1016/S1474-4422(11)70305-2.
35. O. Fernandez, G. Izquierdo, V. Fernandez et al. Adiposederived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE. 2018. No. 13 (5): e0195891. DOI: 10.1371/ journal.pone.0195891.
36. S. Llufriu, M. Sepulveda, Y. Blanco et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE. 2014. No. 9 (12): e113936. DOI: 10.1371/journal.pone.0113936.
37. F. D. Lublin, J. D. Bowen, J. Huddlestone et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014. Vol. 3, Issue 6. Р. 696—704. DOI: 10.1016/j.msard.2014.08.002.
38. P. Petrou, I. Kassis, N. Levin et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020. No. 143 (12). Р. 3574—3588. DOI: 10.1093/brain/awaa333.
39. C. F. Lucchinetti, B. F. Popescu, R. F. Bunyan et al. Inflammatory cortical demyelination in early multiple sclerosis. J Med. 2011. No. 365 (23). Р. 2188—2197. DOI: 10.1056/NEJMoa1100648.
40. R. Magliozzi, O. Howell, A. Vora et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007. No. 130 (Pt. 4). Р. 1089—1104. DOI: 10.1093/brain/ awm038.
41. Reich D. S., Lucchinetti C. F., and Calabresi P. A. Multiple sclerosis. J Med. 2018. No. 378 (2). Р. 169—180. DOI: 10.1056/ NEJMra1401483.
 42. J. Gruchot, V. Weyers, P. Gottle et al. The molecular basis for remyelination failure in multiple sclerosis. Cells. 2019. No. 8 (8). Р. 825. DOI: 10.3390/cells8080825.
43. Karussis D. Immunotherapy of multiple sclerosis: the state of the art. BioDrugs. 2013. No. 27 (2). Р. 113—148. DOI: 10.1007/s40259-013-0011-z.
44. M. S. Freedman, A. Bar-Or, H. L. Atkins et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler. 2010. No. 16 (4). Р. 503—510. DOI: 10.1177/1352458509359727.
45. N. J. Scolding, M. Pasquini, S. C. Reingold, J. A. Cohen, International Conference on Cell-Based Therapies for Multiple Sclerosis. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017. Vol. 140, Issue 11. Р. 2776—2796. DOI: 10.1093/ brain/awx154.
46. S. Pluchino, G. Martino, The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis. J Neurol Sci. 2008. No. 265 (1—2). Р. 105—110. DOI: 10.1016/j. jns.2007.07.020.
47. N. H. Riordan, I. Morales, G. Fernandez et al. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018. No. 16 (1). Р. 57. DOI: 10.1186/s12967-018-1433-7.